scholarly journals Redox/pH-Responsive 2-in-1 Chimeric Nanoparticles for the Co-Delivery of Doxorubicin and siRNA

Polymers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 4362
Author(s):  
Hsi-Chin Wu ◽  
Wei-Ting Kuo
Keyword(s):  
Hyaluronic Acid ◽  
Delivery System ◽  
Rna Silencing ◽  
Tumor Targeting ◽  
Tumor Therapy ◽  
Smart System ◽  
Chemotherapy Drugs ◽  
Dual Responsive ◽  
Interfering Rna ◽  
Structurally Stable

The co-delivery of chemotherapy drugs and gene-suppressing small interfering RNA (siRNA) show promise for cancer therapy. The key to the clinical realization of this treatment model will be the development of a carrier system enabling the simultaneous delivery (“co-delivery” instead of combinatorial delivery) of chemotherapy and siRNA agents to cancer. In this study, a co-delivery system was developed from two individual components to form one integrated nanovehicle through a redox-sensitive thiol–disulfide bond for the synergistic delivery of chemotherapy and RNA silencing: doxorubicin (Dox)-loaded N,O-carboxymethyl chitosan (NOCC) complex with a thiolated hyaluronic acid (HA-SH) nanocarrier and dopamine (Dopa)-conjugated thiolated hyaluronic acid (SH-HA-Dopa)-coated calcium phosphate (CaP)-siRNA nanocarrier. The 2-in-1 chimeric nanoparticles (NPs) were structurally stable together in the storage environment and in the circulation. This smart system selectively releases Dox and siRNA into the cytosol. Furthermore, equipped with the tumor-targeting component HA, the co-delivery system shows specific targeting and high cellular uptake efficiency by receptor-mediated endocytosis. In summary, these dual-responsive (redox and pH), tumor-targeting smart 2-in-1 chimeric NPs show promise to be employed in functional co-delivery and tumor therapy.

scholarly journals Reactive oxygen species and enzyme dual-responsive biocompatible drug delivery system for targeted tumor therapy

2020 ◽  
Vol 324 ◽  
pp. 330-340 ◽  
Author(s):  
Ning Zhao ◽  
Bingbing Ding ◽  
Ying Zhang ◽  
Jessica L. Klockow ◽  
Ken Lau ◽  
...  
Keyword(s):  
Reactive Oxygen Species ◽  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Tumor Therapy ◽  
Reactive Oxygen ◽  
Oxygen Species ◽  
Dual Responsive

Fabrication of dual responsive co-delivery system based on three-armed peptides for tumor therapy

Biomaterials ◽  
2016 ◽  
Vol 92 ◽  
pp. 25-35 ◽  
Author(s):  
Si Chen ◽  
Qi Lei ◽  
Shi-Ying Li ◽  
Si-Yong Qin ◽  
Hui-Zhen Jia ◽  
...  
Keyword(s):  
Delivery System ◽  
Tumor Therapy ◽  
Dual Responsive

A MSN-based tumor-targeted nanoplatform to interfere with lactate metabolism to induce tumor cell acidosis for tumor suppression and anti-metastasis

Nanoscale ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 2966-2972 ◽  
Author(s):  
Zhao-Xia Chen ◽  
Miao-Deng Liu ◽  
Deng-Ke Guo ◽  
Mei-Zhen Zou ◽  
Shi-Bo Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Tumor Cell ◽  
Drug Delivery System ◽  
Delivery System ◽  
Tumor Suppression ◽  
Tumor Targeting ◽  
Tumor Therapy ◽  
Lactate Metabolism ◽  
Metastasis Research

A tumor targeting drug delivery system was designed to interfere with lactate metabolism for tumor therapy and anti-metastasis research.

scholarly journals A New NT4 Peptide-Based Drug Delivery System for Cancer Treatment

Molecules ◽  
2020 ◽  
Vol 25 (5) ◽  
pp. 1088 ◽  
Author(s):  
Jlenia Brunetti ◽  
Sara Piantini ◽  
Marco Fragai ◽  
Silvia Scali ◽  
Giulia Cipriani ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Tumor Targeting ◽  
Colon Adenocarcinoma ◽  
Human Colon ◽  
In Vitro Cytotoxicity ◽  
Cancer Tissue ◽  
Chemotherapy Drugs

The development of selective tumor targeting agents to deliver multiple units of chemotherapy drugs to cancer tissue would improve treatment efficacy and greatly advance progress in cancer therapy. Here we report a new drug delivery system based on a tetrabranched peptide known as NT4, which is a promising cancer theranostic by virtue of its high cancer selectivity. We developed NT4 directly conjugated with one, two, or three units of paclitaxel and an NT4-based nanosystem, using NIR-emitting quantum dots, loaded with the NT4 tumor-targeting agent and conjugated with paclitaxel, to obtain a NT4-QD-PTX nanodevice designed to simultaneously detect and kill tumor cells. The selective binding and in vitro cytotoxicity of NT4-QD-PTX were higher than for unlabeled QD-PTX when tested on the human colon adenocarcinoma cell line HT-29. NT4-QD-PTX tumor-targeted nanoparticles can be considered promising for early tumor detection and for the development of effective treatments combining simultaneous therapy and diagnosis.

Integration of phospholipid-hyaluronic acid-methotrexate nanocarrier assembly and amphiphilic drug–drug conjugate for synergistic targeted delivery and combinational tumor therapy

2018 ◽  
Vol 6 (7) ◽  
pp. 1818-1833 ◽  
Author(s):  
Yang Li ◽  
Huabing Zhang ◽  
Yilin Chen ◽  
Jinyuan Ma ◽  
Jinyan Lin ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Delivery System ◽  
Targeted Delivery ◽  
Tumor Therapy ◽  
Drug Conjugate ◽  
Amphiphilic Drug ◽  
Polymeric Delivery ◽  
Dual Drug

A novel synergistic-targeting polymeric delivery system was developed to carry drug–drug conjugate for boosting dual-drug co-delivery and combinational tumor therapy.

Phenylboronic acid-functionalized polyaminoglycoside as an effective CRISPR/Cas9 delivery system

2021 ◽  
Author(s):  
Meiyu Shao ◽  
Yu Qi ◽  
Dandan Sui ◽  
Fu-Jian Xu
Keyword(s):  
Delivery System ◽  
Tumor Targeting ◽  
Phenylboronic Acid ◽  
System P

One tumor-targeting, phenylboronic acid-functionalized polyaminoglycoside (SS-HPT-P) was proposed as a safe and effective CRISPR/Cas9 delivery system for the treatment of carcinoma.

Sign in / Sign up

Export Citation Format

Share Document